Chemomab appoints Gwen Melincoff to board, names her nominating committee chair

• Chemomab appointed Gwen Melincoff to its board as a Class I director, naming her chair of the nominating and governance committee.
• Melincoff is managing director at Gemini Advisors; previously led business development at BTG International, Shire, Adolor, Eastman Kodak health care units.
• Directors Claude Nicaise and Jill Quigley resigned from the board, stepping down from the audit committee; no disputes cited.
• Neil Cohen and Nissim Darvish joined the audit committee; Cohen will chair alongside Darvish, Alan Moses.
• Cohen also resigned as chair of the nominating committee; the board will have five directors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003058), on June 02, 2026, and is solely responsible for the information contained therein.